This NYSE traded small cap biotech stock has major catalysts on the horizon – Details and Symbol Here <<
Some of the best opportunities can be found in pullbacks.
Most times, at least with larger cap stocks, the pullbacks are temporary. And if spotted in time, they can be wildly profitable.
Look at Microsoft (SYM:MSFT).
Every time it pulls back, it’s an opportunity – especially when three key technical indicators align in oversold territory. That includes RSI, Full Stochastics and Williams’ %R. In fact, if you pull up a year one chart of MSFT with those technical indicators, you can see that about 90% of the time when MSFT dips and those indicators all dip into oversold territory, MSFT bounces.
Even better, with MSFT at strong support at its 200-day moving averages with all three technical indicators in oversold territory, MSFT is a screaming buy.
Nike l(SYM:NKE)
Not only did it catch support at its 50-day moving average, but it’s also starting to pivot higher from over-extensions on RSI, MACD and Williams’ %R. From its last traded price of $82.45, we’d like to see it initially refill its bearish gap a around $87.50.
It also looks like earnings negativity has been priced into the stock, too.
Helping, analysts at Truist just upgraded NKE to a buy rating with a price target of $97. “The firm notes it has been cautious on Nike since Fall of 2023 and still views a turnaround process as long and uncertain, but adds that it is now ‘more optimistic’ as investor expectations finally seem to accurately reflect this reality,” as reported by TheFly.com.
Johnson & Johnson (SYM:JNJ)
Even Johnson & Johnson (JNJ) has become technically oversold on RSI, Fast Stochastics and Williams’ %R. Better, after pulling back from about $168 to $160.36, it appears the JNJ stock caught strong support and could push aggressively higher.
Helping, RBC Capital just raised its price target on JNJ to $178 with an outperform rating.
“Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end,” RBC added, as noted by TheFly.com.
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,500 and was received/will be received from Interactive Offers.
This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Financial Markets Daily.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 10/11/24.